Clinical Trials
36 trialsNCT04322006 2026-05-13
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
Phase 1/2 Completed
NCT07480733 2026-05-08
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
NCT03810339 2026-04-23
Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Sun Yat-sen University
Phase 2 Recruiting
NCT06832982 2026-04-09
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
Shanghai Pushi Medical Science Co. Ltd
Phase 1 Recruiting
NCT07508761 2026-04-02
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Nanjing Immunophage Biotech Co., Ltd
Phase 1/2 Not yet recruiting
NCT06953323 2026-03-27
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT07392736 2026-02-06
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Advenchen Laboratories, LLC
Phase 1/2 Recruiting
NCT05518045 2026-02-04
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Active not recruiting
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT07245901 2025-11-24
Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Not yet recruiting
NCT06682780 2025-09-25
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT06868199 2025-09-12
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT06088004 2025-08-22
Phase â… /â…¡ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1/2 Recruiting
NCT06208410 2025-07-25
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 1/2 Recruiting
NCT04914286 2025-05-14
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Completed
NCT05830539 2025-05-02
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Completed
NCT06873854 2025-03-13
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 2 Not yet recruiting
NCT05188664 2025-02-17
Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
LaNova Medicines Limited
Phase 1/2 Completed
NCT06038396 2025-01-29
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT06117566 2024-11-25
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shanghai Jiatan Pharmatech Co., Ltd
Phase 1/2 Recruiting
NCT06410703 2024-10-31
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Canwell Biotech Limited
Phase 1/2 Recruiting
NCT06490068 2024-07-08
Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT03874897 2024-04-30
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Phase 1 Completed
NCT04301557 2024-04-23
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05576961 2024-01-23
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
Sun Yat-sen University
Phase 1/2 Unknown
NCT04357756 2023-09-13
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1 Completed
NCT05699811 2023-04-28
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT04169672 2023-03-02
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Hutchmed
Phase 2 Completed
NCT04481009 2022-12-12
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1/2 Completed
NCT05502393 2022-08-16
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Unknown
NCT05165849 2022-05-20
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2 Withdrawn
NCT05369286 2022-05-11
A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
Maxinovel Pty., Ltd.
Phase 1 Unknown
NCT04337463 2021-05-17
ATG-008 Combined With Toripalimab in Advanced Solid Tumors
Sichuan University
Phase 1/2 Unknown
NCT04713761 2021-01-26
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown